Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus

Ekiz-Bilir, Betul; Bilir, Bülent; Aydın, Murat; Soysal-Atile, Neslihan

doi:10.5114/aoms.2018.79488

Cited by 31 publications

(36 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several previous studies have shown higher endocan levels in T2D [8,10,11], some others showed the opposite, i.e. lower endocan levels in T2D than in controls [12].…”

Section: Introductionmentioning

confidence: 77%

Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes

Klisić

Kavarić

Stanišić

et al. 2020

aoms

View full text Add to dashboard Cite

Introduction: We aimed to examine serum endocan level and the summary involvement of dyslipidemia, oxidative stress (OS) and inflammation by calculation of its comprehensive score (i.e. Dyslipidemia-Oxy-Inflammation (DOI) score) in relation to glucoregulation in subjects with prediabetes and overt type 2 diabetes (T2D). Material and methods: A total of 59 patients with prediabetes and 102 patients with T2D were compared with 117 diabetes-free controls. Glycated hemoglobin (HbA 1c), inflammation, OS and lipid parameters were measured. Associations of clinical data with HbA 1c level were tested with univariate and multivariate logistic ordinal regression analysis. HbA 1c as a dependent variable is given at the ordinal level (i.e. < 5.7%; 5.7-6.4%, > 6.4%, respectively). Results: Endocan was significantly higher in the T2D group than in the controls. As endocan concentration rose by 1 unit, the probability for higher HbA 1c concentration increased by more than 3 times (OR = 3.69, 95% CI: 1.84-7.01, p < 0.001). Also, a rise in the dyslipidemia score, oxy score, inflammation score and DOI score by 1 unit increased the probability of higher HbA 1c concentration by 19%, 13%, 51% and 11%, respectively. In the models, after adjustment for confounding variables, endocan and DOI score remained independent predictors of HbA 1c level. Conclusions: Endocan and DOI score are independently correlated with HbA 1c in patients with prediabetes and overt T2D.

show abstract

“…Although several previous studies have shown higher endocan levels in T2D [8,10,11], some others showed the opposite, i.e. lower endocan levels in T2D than in controls [12].…”

Section: Introductionmentioning

confidence: 77%

Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes

Klisić

Kavarić

Stanišić

et al. 2020

aoms

View full text Add to dashboard Cite

show abstract

“…It is known that both diabetics and smoking leads to endothelial dysfunction 3,27 . In the literature, several studies reported that endocan levels were determined to be higher in diabetic patients compared to control groups 27,28 . In our study, we formed the control group from patients who did not smoke and did not have any disease.…”

Section: Discussionmentioning

confidence: 99%

Endocan as a potential biomarker of disease severity and exacerbations in COPD

İn

Kuluöztürk

Turgut

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction Endocan is a proteoglycan that is regarded as a novel marker of endothelial dysfunction. Endothelial dysfunction in pulmonary vascular bed is known to play an important role for the pathogenesis of COPD. Objective This study aimed to determine serum endocan levels in patients with stable COPD and acute exacerbation of COPD (AECOPD) and to test the relationship between serum endocan levels and exacerbations. Methods This study enrolled a total of 55 COPD patients, 24 of which had AECOPD and 31 had stable COPD. All patients’ basic demographic and clinical data were recorded and blood samples were collected. Results Serum endocan levels were significantly higher in the AECOPD group compared to the stable COPD and control groups (for both p < 0.001) and stable COPD group had higher levels than the control group (p < 0.005). Additionally, serum endocan levels were negatively correlated with FVC, FEV1, partial oxygen pressure and oxygen saturation (r = −0.30, p = 0.03; r = −0.34, p = 0.01; r = −0.34, p = 0.01 and r = −0.36, p = 0.007 respectively), and positively correlated with disease duration and systolic pulmonary artery pressure (r = 0.47, p < 0.001; r = 0.31, p = 0.02 respectively). A cut‐off value of 434.29 pg/ml for endocan predicted exacerbation with a sensitivity of 79% and a specificity of 84% (AUC: 0.778, 95% Cl 0.648‐0.909; p < 0.001). Logistic regression analysis revealed that increased endocan levels was independent predictor of COPD exacerbation (OR = 9.32, 95%CI, 1.64‐52.95; p = 0.01). Conclusion Endocan may be a novel biomarker for detection of endothelial dysfunction and prediction of exacerbations in patients with COPD.

show abstract

“…Another research group investigated the role of endocan and another glycoprotein, endoglin, in CKD caused by diabetes mellitus [ 20 ]. The study included diabetic patients with and without diabetic nephropathy (DN), and controls.…”

Section: Endocan In Ckdmentioning

confidence: 99%

The Role of Endocan in Selected Kidney Diseases

Nalewajska

Gurazda

Marchelek-Myśliwiec

et al. 2020

IJMS

View full text Add to dashboard Cite

Endocan, previously referred to as an endothelial-cell-specific molecule-1 (ESM-1) is a member of a proteoglycan family that is secreted by vascular endothelial cells of different organs, mainly lungs and kidneys. It is assumed to participate in endothelial activation and the triggering of inflammatory reactions, especially in microvasculatures. Thanks to its solubility in human fluids, i.e., urine and blood plasma, its stability and its low concentrations in physiological conditions, endocan has been proposed as an easily available, non-invasive biomarker for identifying and predicting the course of many diseases. Recently, endocan has been studied in relation to kidney diseases. In general, endocan levels have been linked to worse clinical outcomes of renal dysfunction; however, results are conflicting and require further evaluation. In this review, authors summarize available knowledge regarding the role of endocan in pathogenesis and progression of selected kidney diseases.

show abstract

Evaluation of endocan and endoglin levels in chronic kidney disease due to diabetes mellitus

Cited by 31 publications

References 25 publications

Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes

Endocan and a novel score for dyslipidemia, oxidative stress and inflammation (DOI score) are independently correlated with glycated hemoglobin (HbA1c) in patients with prediabetes and type 2 diabetes

Endocan as a potential biomarker of disease severity and exacerbations in COPD

The Role of Endocan in Selected Kidney Diseases

Contact Info

Product

Resources

About